# PATENT COOPERATION TREATY

# **PCT**

#### INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applican 38506-00	nt's or agent's file reference 025	FOR FURTHER ACTION		cation of Transmittal of International Search orm PCT/ISA/220) as well as, where applicable, ow.			
International application No. PCT/US03/38950		International filing date (day/month/year) 10 December 2003 (10.12.2003)		(Earliest) Priority Date (day/month/year) 10 December 2002 (10.12.2002)			
	Applicant MEDSTAR RESEARCH INSTITUTE						
according	This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.  This international search report consists of a total of						
1. Basi a.							
b.	Authority (Rule 23.1(b)).	and/or amino acid sequence disclo		international application furnished to this international application, the international			
<u> </u>	contained in the internationa	al application in written form.					
<u> </u>	₹ ·	national application in computer read	able form.				
<u> </u>	furnished subsequently to thi	·					
<u> </u>	₹ · · · · · ·	is Authority in computer readable fo		the state of the disclosure in the			
	international application as fi	quently furnished written sequence lis filed has been furnished.	sting does n	tot go beyond the disclosure in the			
	the statement that the inform been furnished.	nation recorded in computer readable	: form is ide	entical to the written sequence listing has			
2.	Certain claims were found	unsearchable (See Box I).					
3.	Unity of invention is lacking	g (See Box II).					
4. Wit	th regard to the title,  the text is approved as submi	itted by the annlicant					
	₹ ```	by this Authority to read as follows:	:				
5. Wit	5. With regard to the abstract,						
	the text is approved as submi	itted by the applicant.					
	_		-	is it appears in Box III. The applicant may, it, submit comments to this Authority.			
6. The	as suggested by the applicant because the applicant failed to because this figure better cha	to suggest a figure.	·	None of the figures			
_	, ,						

Form PCT/ISA/210 (first sheet) (July 1998)

### INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/38950

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)					
This	internati	onal report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1.		Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
2.		Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
3.		Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box	П Оь	servations where unity of invention is lacking (Continuation of Item 2 of first sheet)			
		ional Searching Authority found multiple inventions in this international application, as follows: ontinuation Sheet			
1.		As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2.		As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3.		As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
4.	$\boxtimes$	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-10, and 20-23, with regard to SPP1, MIG, and IP10			
Rema	ark on P	Protest The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.			

#### INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/38950

A. CLASSIFICATION OF SUBJECT MATTER  IPC(7) : C12Q 1/68 US CL : 435/6								
According to International Patent Classification (IPC) or to both national classification and IPC								
B. FIEL	DS SEARCHED							
	Minimum documentation searched (classification system followed by classification symbols)  U.S.: 435/6							
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched								
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet								
	UMENTS CONSIDERED TO BE RELEVANT							
Category *	Citation of document, with indication, where a		Relevant to claim No.					
X,P	US 2003/0148334 A1 (SUN et al) 07 August 2003 (	07.08.2003), abstract, Table 1.	1-4, 8-9					
x	ZIMMER. R. et al. Expression Profiling and Interferon-beta Regulation of Liver Metastases in Colorectal Cancer Cells. Clinical and Experimental Metastasis. 2002. Vol 19, pages 541-550, see abstract, Fig. 2.		1-4, 8-9					
x	LI, S. et al. Regression of Tumors by IFN-a Electron the Reesponsible Genes by cDNA Array. Gene The 397, see abstract	1-4, 8-9						
Further	documents are listed in the continuation of Box C.	See patent family annex.						
Special categories of cited documents:		"T" later document published after the inter date and not in conflict with the applica						
	defining the general state of the art which is not considered to be lar relevance	principle or theory underlying the inver	.•					
	plication or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be considered.						
	which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	when the document is taken alone  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination						
"O" document referring to an oral disclosure, use, exhibition or other means		being obvious to a person skilled in the						
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent family						
Date of the ac	ctual completion of the international search	Date of mailing of the international search	Nº2005					
	2004 (09.12.2004)							
	ailing address of the ISA/US	Authorized officer						
Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Jehanne S Sitton Nell Slunsfol						
P.O. Box 1450		Telephone No. 571-272-0500						
Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		10. 3/1-2/2-0300	l'					

PCT/US03/38950

## INTERNATIONAL SEARCH REPORT

#### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group 1, claim(s) 1-10 and 20-23, drawn to a method for predicting the likelihood that a subject will develop collaterals by assaying the expression of at least 3 genes.

Group 2, claim(s) 11-16, drawn to a method for predicting the likelihood that a subject will develop collaterals by assaying for a SNP or altered DNA methylation patterns in at least 3 genes.

Group 3, claim(s) 17-19, drawn to a kit comprising oligonucleotides for detecting genes from table 1.

Group 4, claim(s) 24-28, drawn to a method of promoting collateral formation by administering a composition that decreases expression of at least one gene in table 2 and/or increases expression of at least one gene in table 3.

The inventions listed as Groups 1-4 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature is deemed to be the involvement of genes in the development of collaterals. Claim 1, for example, is drawn to a method of assaying the expression level of at least 3 genes in a subject for the purpose of determining likelihood of developing collateral. Such assaying is taught by Zimmer and Thomas, Clinical & Experimental Metastasis, vol. 19, pages 541-550, 2002. Therefore, the claims do not relate to a single general inventive concept as they lack the same or corresponding special technical feature over the prior art. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

For Group 1, it is noted that claims which do not specify any genes from the tables will be searched according to the full scope of the claims. Therefore, the search for claims 1, 2, 8-10, and 20-23 will not be limited to any specific genes, however claim 2 will be limited to searching 3 genes. For claim 5-7, applicant is required to elect a specific combination of genes from the table. The first named species that will be searched with the generic claims will be IP10, MIG, and SPP1. Therefore, if applicant does not elect any additional groups, the generic claims will be searched to their full scope, claims 2-4 will be limited to any 3 genes, and claims 5-7 will be limited to searching IP10, MIG, and SPP1. With regard to claims 2-4, any additional combination of 5, 10, or 20 genes are considered to be a separate species and will require additional fees. Applicant may wish to elect more than one combination of genes, generically for claims 2-4, and specifically for claims 5-7. If so, it is noted that each combination will also be considered a separate species.

For group 2: for claim 13, applicant is required to elect a specific combination of genes from the table. It is noted that claims which do not specify any genes from the tables will be searched according to the full scope of the claims. Therefore, the search for claims 11, and 14-16 will not be limited to any specific genes, however claim 12 will be limited to searching 3 genes. Applicant is requested to indicate the combination of specific genes from table 1 which claim13 will be limited to. If applicant wishes to further elect any additional combinations from claim 12, applicant may do so, however such is considered a separate species. Further, Applicant may wish to elect more than one specific combination of genes. If so, it is noted that each combination will be considered a separate species.

For Group 3: applicant is required to elect a specific combination of genes from table 1 to which the claimed oligonucleotides will be limited. Applicant may wish to elect more than one combination. If so, it is noted that each combination will be considered a separate species.

For Group 4: applicant is required to elect a specific combination of genes from tables 2 and/ or 3 to which the claims will be limited. Further, for claim 28, applicant is required to indicate a specific gene from table 3 for protein administration. Applicant may wish to elect more than one combination of genes for claims 24 and 28. If so, it is noted that each combination will be considered a separate species.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The genes listed in the various tables are

#### INTERNATIONAL SEARCH REPORT

PCT/US03/38950

drawn to structurally and functionally distinct products. These structurally and functionally different products lack the same or corresponding special technical feature.
Continuation of B. FIELDS SEARCHED Item 3:
Caplus, medline, Genbank search terms: angiogenesis, collateral, blood vessel, gene, nucleic acid, mRNA, RNA, expression, array, chip, SPP1, IP10, MIG, SCYB10, SCYB9

Form PCT/ISA/210 (second sheet) (July 1998)